Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 5/20 | 0.51 |
| ▸ | TYMS | P04818 | 8/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820926 | 0.80 | TYMS (0.44) | TYMSXDHDHFRCYP1A2 | |
| SCHEMBL4626229 | 0.78 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL2069734 | 0.77 | CRHR1 (0.65) | CRHR1 | |
| SCHEMBL13838861 | 0.77 | CRHR1 (0.51) | CRHR1XDH | |
| SCHEMBL2070607 | 0.77 | CRHR1 (0.65) | CRHR1TYMS | |
| SCHEMBL2071976 | 0.73 | CRHR1 (0.60) | CRHR1CYP1A2 | |
| SCHEMBL2070441 | 0.73 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL18520802 | 0.73 | TYMS (0.44) | TYMSXDHDHFR | |
| SCHEMBL2069914 | 0.73 | TYMS (0.41) | TYMSXDHCYP1A2 | |
| SCHEMBL24905894 | 0.72 | TYMS (0.42) | TYMSDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | CRHR1 1/4885TYMS 3892/4885FGFR1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.